Corrigendum: Optimized riboswitch-regulated AAV vector for VEGF-B gene therapy

Frontiers in Medicine

Medicine

Seppo Ylä-Herttuala¹  Sanna K. Peltola²  Igor Oruetxebarria²  Saana Lepola²  Hanna M. Leinonen²  Tiina Nieminen²  Kari J. Airenne²  Eevi M. Lipponen²  Lionel Galibert²  Petra Tikkanen²  Hanna P. Lesch²  Anniina J. Valkama²  Reetta A. E. Eriksson³  Piia Käyhty³ 

[1] A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland;Gene Therapy Unit and Research Center, Kuopio University Hospital, Kuopio, Finland;Kuopio Center for Gene and Cell Therapy, Kuopio, Finland;Kuopio Center for Gene and Cell Therapy, Kuopio, Finland;A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland;

关键词: riboswitch;    ON-switch;    gene therapy;    AAV (adeno-associated virus);    VEGF-B;    tetracycline;    transgene expression regulation;   

DOI  :  10.3389/fmed.2023.1143748

 received in 2023-01-13, accepted in 2023-02-13,  发布年份 2023

来源: Frontiers

【 授权许可】

Unknown   
Copyright © 2023 Eriksson, Nieminen, Galibert, Peltola, Tikkanen, Käyhty, Leinonen, Oruetxebarria, Lepola, Valkama, Lipponen, Lesch, Ylä-Herttuala and Airenne.